Elicio Therapeutics Reports Complete Responses with ELI-002 7P and Checkpoint Inhibitors in Pancreatic Cancer
ELTX is trading near its 52-week low of $2.66 (12% below the low) on elevated volume (14× avg).
Summary
Elicio Therapeutics reported preliminary clinical observations showing complete responses in three pancreatic cancer patients treated with ELI-002 7P followed by checkpoint inhibition, leading to plans for a new Phase 1 combination study.
Key Events · Product Development and Regulatory · ELTX
-
Preliminary Clinical Observations
Three patients with metastatic mKRAS pancreatic cancer, who progressed on ELI-002 7P in the Phase 2 AMPLIFY-7P study, achieved 100% confirmed complete radiographic and metabolic responses after subsequent nivolumab-based therapy.
-
Rare Complete Responses
Complete responses are rarely observed (0-8%) in metastatic pancreatic cancer, especially in microsatellite stable (MSS) / mismatch repair proficient (MMR-p) patients, which historically show limited response to immune checkpoint inhibitors.
-
Planned Phase 1 Study
Elicio intends to initiate a Phase 1 study to evaluate ELI-002 7P in combination with checkpoint inhibition in first-line metastatic mKRAS pancreatic ductal adenocarcinoma (PDAC), subject to funding.
-
Strategic Pivot After Phase 2 Failure
This news follows the recent announcement on June 15, 2026, that ELI-002 7P failed to meet its primary endpoint in the Phase 2 AMPLIFY-7P study, providing a new potential development pathway for the lead candidate.
Analysis · ELTX · Life Sciences
This filing provides a potential path forward for Elicio's lead candidate, ELI-002 7P, after its recent Phase 2 failure. While preliminary, the observation of complete responses in three patients with metastatic pancreatic cancer, a notoriously difficult-to-treat disease, when ELI-002 7P was followed by checkpoint inhibition, offers a new development strategy. This could be crucial for the company, which is operating under a 'going concern' warning and has an active ATM program to raise capital. The planned Phase 1 study, though subject to funding, aims to validate this combination, potentially shifting the investment thesis from a failed monotherapy to a promising combination approach.
At the time of this filing, ELTX was trading at $2.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.7M. The 52-week trading range was $2.66 to $16.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.